Haemonetics
324 hedge funds and large institutions have $2.68B invested in Haemonetics in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 117 increasing their positions, 110 reducing their positions, and 55 closing their positions.
166% more call options, than puts
Call options by funds: $6.75M | Put options by funds: $2.54M
6% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 110
4% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 55
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 328 → 324 (-4)
6.15% less ownership
Funds ownership: 108.62% → 102.48% (-6.1%)
34% less capital invested
Capital invested by funds: $4.07B → $2.68B (-$1.39B)
Top Buyers
Top Sellers
| 1 |
Holocene Advisors
New York
|
-$82M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$51.9M |
| 4 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
-$41.9M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$25.2M |
HAE Hedge Fund Activity: Q1 2026 in Review
324 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2026, worth a combined $2.68B — down 34% from $4.07B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new HAE positions and 55 closed out — a net gain of 2 holders — while 117 added to existing stakes and 110 trimmed.
The largest buyer was Invenomic Capital Management, opening a new position worth an estimated $43.3M. The largest seller was Holocene Advisors, cutting an estimated $82M.
- 324 institutional investors held Haemonetics (HAE) as of Q1 2026, down from 328 in Q4 2025.
- Funds reported $2.68B of Haemonetics stock for Q1 2026, down 34% quarter-over-quarter.
- 57 funds opened new Haemonetics positions in Q1 2026 and 55 closed out, a net change of +2 holders.
- The largest Haemonetics buyer in Q1 2026 was Invenomic Capital Management, an estimated $43.3M added.
- The largest Haemonetics seller in Q1 2026 was Holocene Advisors, an estimated $82M sold.
Based on aggregated 13F filings for Q1 2026.